Document is current
Any future updates will be listed below
-
Authors
Walker, Callum
Kollarovic, Gabriel https://orcid.org/0000-0002-3159-7781
Weekes, Daniel
Trendell, Jennifer https://orcid.org/0000-0002-5517-0352
Hoffmann, Ricarda M.
Martin, Alexia
Ferro, Riccardo https://orcid.org/0000-0001-6532-4856
Navarro-Llinas, Blanca
Hitchen, Luke
Pardo Calvo, Mercedes https://orcid.org/0000-0002-3477-9695
Balan, Nicolae
Kemp, Harriet
Carroll, Alexandra
Davidson, Kathryn
Nath, Sarmi https://orcid.org/0000-0002-8302-7094
D’Uonno, Nadja https://orcid.org/0009-0008-5585-7083
Lu, Ruifang
Starling, Chris https://orcid.org/0009-0007-5100-6663
Otten, Marieke https://orcid.org/0000-0002-1395-2647
Iakobachvili, Nino
Marcozzi, Chiara
Rahman, Ilhan
Quist, Jelmar
Yu, Lu https://orcid.org/0000-0001-8378-9112
Krastev, Dragomir B. https://orcid.org/0000-0003-4298-7272
Amodeo, Valeria
Roxanis, Ioannis
Grigoriadis, Anita https://orcid.org/0000-0003-3434-201X
Bayliss, Richard https://orcid.org/0000-0003-0604-2773
Choudhary, Jyoti https://orcid.org/0000-0003-0881-5477
Haider, Syed https://orcid.org/0000-0001-6685-5480
Pines, Jonathon https://orcid.org/0000-0002-5227-6004
Pettitt, Stephen J.
Lord, Christopher J. https://orcid.org/0000-0002-3226-0515
Tutt, Andrew N. J. https://orcid.org/0000-0001-8715-2901
-
Funding
Funding for this research was provided by:
Cancer Research UK (DRCRPGNov21y100001)
Breast Cancer Research Foundation (BCRF-23-199)
- License Information
-
More Information
Article History
Received: 8 April 2022
Accepted: 27 January 2026
First Online: 11 March 2026
Competing interests
: C.J.L. makes the following disclosures: receives and/or has received research funding from: AstraZeneca, Merck KGaA, Artios, Neophore. Received consultancy, SAB membership or honoraria payments from: FoRx, Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, Neophore, Glaxo Smith Kline, Dawn Bioventures. Has stock in: Tango, Ovibio, Hysplex, Tesselate. C.J.L. is also a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from their development and use as part of the ICR “Rewards to Discoverers” scheme and also reports benefits from this scheme associated with patents for PARP inhibitors paid into CJL’s personal account and research accounts at the Institute of Cancer Research. A.N.J.T. is/has been a consultant for AstraZeneca, Merck KGaA, Artios, Pfizer, Vertex, GE Healthcare, Inbiomotion, Prime Oncology, Medscape Education, EMPartners, VJ Oncocogy, Gilead and MD Anderson Cancer Centre; has received grant/research support from AstraZeneca, Myriad, Medivation and Merck KGaA, CRUK and Breast Cancer Now; is a stockholder in Inbiomotion; and is also a named inventor on patents describing the use of PARP repair inhibitors in DNA repair deficient cancers and stands to gain from their development and use. The remaining authors declare no competing interests.
